Efficacy and Safety of Divaza for The Correction of Oxidative Disturbances in Patients with Cerebral Atherosclerosis: A Randomized Controlled Trial
Bibliographic record
Abstract
Abstract Objective: To determine if Divaza was safe and effective for the correction of oxidative disturbances and to stabilize cognitive impairment in patients with cerebral atherosclerosis. Study design: 12-week multicenter, randomized, double-blind, placebo-controlled, prospective trial in parallel groups. Setting: 10 clinical centers across the Russian Federation. Interventions: Patients were randomized into two groups and instructed to take either 2 tablets of the study drug or placebo 3 times per day in conjunction with basic therapy. Outcomes: The primary outcome was a change in the average endogenous antioxidant potential after the completion of the study. The laboratory indicators of oxidative stress were analyzed at baseline and then after 12 weeks of therapy using iron-induced chemiluminescence analysis. The Montreal cognitive assessment test was used as a secondary outcome measure to evaluate cognitive impairment at the end of the study. Results: 124 outpatients with a mean age of 60.7±7.6 years were enrolled and randomly assigned to receive Divaza (n=65) or placebo (n=59). The Administration of Divaza restored the activity of the endogenous antioxidant system. The change in the average level of lipoprotein resistance to oxidation after 12 weeks of therapy, compared to the baseline, was significantly higher in the Divaza group (14.8±14.7 [14.8±14.7] seconds latent period versus 6.4±16.9 [6.9±16.7] seconds in the placebo group (p=0.007 [p=0.0107]). In addition, a recovery of cognitive impairment was observed in all patients of the Divaza group at the end of treatment; this was significantly better when compared with the placebo group (100 [100] % versus 89.5 [89.1] %, respectively, p=0.0272 [p=0.0128]). The treatment was safe, well-tolerated, and had a high compliance rate. Conclusions: Divaza is a safe and effective therapeutic option for attenuating oxidative stress and recovery of cognitive impairment in patients with cerebral atherosclerosis. Trial registration: clinicaltrials.gov NCT03485495, of April 02, 2018.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.007 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".